SLEEP 2020: AXS-12 (reboxetine) treats narcolepsy, Phase II trial results to be announced.

Hypersomnia is an oversleeping disorder with two main types: primary narcolepsy and recurrent narcolepsy.
narcolepsy may be caused by brain damage or severe depressive disorders, uremia and fibromyalgia.
may also be a symptom of sleep disorders such as sleep apnea, sleep apnea, sleep foot movements, and periodic limb movements.
also lead to narcolepsy, such as taking certain medications (some psychotic drugs) or alcohol abuse.
, a biopharmaceutical company dedicated to developing new treatments for central nervous system (CNS) disease, announced today that it will publish data on the effectiveness and safety of AXS-12 for narcolepsy at the 2020 Sleep Conference (SLEEP 2020).
AXS-12 (reboxetine) is a highly selective dethynephrine reuptake inhibitor used to treat narcolepia.
AXS-12 regulates epinephrine activity to promote sobriety, maintain muscle dystas and enhance cognitive ability.
AXS-12 has been awarded the U.S. Food and Drug Administration's (FDA) breakthrough therapy title and orphan drug title for the treatment of narcolepsy.
AXS-12 is still a research compound that has not been approved by the FDA.
.